Evidence map›Paper›PMID 37066289›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controls.

Molly Went, Amit Sud, Charlie Mills, Abi Hyde, Richard Culliford, Philip Law, Jayaram Vijayakrishnan, Ines Gockel, Carlo Maj, Johannes Schumacher and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Molly WentDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Charlie MillsDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Abi HydeDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Richard CullifordDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Philip LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Jayaram VijayakrishnanDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Ines GockelDepartment of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany.
Carlo MajCenter for Human Genetics, University Hospital of Marburg, Marburg, Germany.
Johannes SchumacherCenter for Human Genetics, University Hospital of Marburg, Marburg, Germany.
Claire PallesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Martin KaiserDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Richard HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Institute of Cancer Research · GBPhilipps University of Marburg · DERoyal Marsden NHS Foundation Trust · GBUniversity Hospital Leipzig · DEUniversity of Birmingham · GB

Funding

Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098216 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI RIBOLI, ELIO · 2003 to 2011
$7.4M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
Imputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9M
Cancer Research UK 25514NCI NIH HHS R01 CA128978NCI NIH HHS U01 CA098216NCI NIH HHS U01 CA098233NCI NIH HHS U01 CA098710NCI NIH HHS U01 CA098758NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome Trust
6 · The paper itself

Abstract

For many cancers there are few well-established risk factors. Summary data from genome-wide association studies (GWAS) can be used in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to identify causal relationships. We performed a MR-PheWAS of breast, prostate, colorectal, lung, endometrial, oesophageal, renal, and ovarian cancers, comprising 378,142 cases and 485,715 controls. To derive a more comprehensive insight into disease aetiology we systematically mined the literature space for supporting evidence. We evaluated causal relationships for over 3,000 potential risk factors. In addition to identifying well-established risk factors (smoking, alcohol, obesity, lack of physical activity), we provide evidence for specific factors, including dietary intake, sex steroid hormones, plasma lipids and telomere length as determinants of cancer risk. We also implicate molecular factors including plasma levels of IL-18, LAG-3, IGF-1, CT-1, and PRDX1 as risk factors. Our analyses highlight the importance of risk factors that are common to many cancer types but also reveal aetiological differences. A number of the molecular factors we identify have the potential to be biomarkers. Our findings should aid public health prevention strategies to reduce cancer burden. We provide a R/Shiny app (https://mrcancer.shinyapps.io/mrcan/) to visualise findings.

Indexed as

aetiologyCancergenome wide association studyMendelian randomisationrisk

Identifiers

PMID37066289
PMCPMC10104236
OpenAlexW4321606014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.